Christoph Boss

Christoph Boss is the Vice President of Medicinal Chemistry, known for his extensive contributions to the field of drug discovery and development. He began his career at Actelion Pharmaceuticals Ltd. and continued at Johnson & Johnson following its acquisition of Actelion. He later advanced to the role of Senior Vice President, Head of Drug Discovery Chemistry at Idorsia Pharmaceuticals. Boss holds a Ph.D. in synthetic organic chemistry from The University of Bern, Switzerland, and completed postdoctoral work at The Scripps Research Institute under Professor Julius Rebek, Jr. He is a co-inventor of Macitentan, marketed as Opsumit® for the treatment of pulmonary hypertension, and Aprocitentan, currently under FDA review for treating difficult types of hypertension. Additionally, he played a key role in identifying Daridorexant, marketed as Quviviq® for the treatment of insomnia disorder. Boss has been recognized with the SCS Industrial Science Award from the Swiss Chemical Society and serves as a council member of both the FHNW Foundation and the Foundation of Swiss Chemical Society.